Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Current Quarter	$0.11	Next Quarter	$-0.19
Current Year	$-0.46	Next Year	$-0.69
QoQ Growth	-272.7%	YoY Growth	-50.0%
3Y EPS CAGR	+26.3%	Target Price	$21.50
Consensus	Buy	Upside	+16.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TBPH	$18.48	+3.24%	566.88K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TBPH	$18.48	+3.2%	566.88K
3
4
5
6

TBPH

TBPH

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Theravance Biopharma Inc. Data in Excel

Get Theravance Biopharma Inc. Data in Excel